Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus

Diabetology International

Volumn 6, Issue 3, 2015, Pages 197-205

  Tanaka, Masami ^a   Sekioka, Risa ^a   Nishimura, Takeshi ^a   Kawai, Toshihide ^a   Meguro, Shu ^a   Irie, Junichiro ^a   Saisho, Yoshifumi ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

C peptide immunoreactivity; Predictive factor; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; BODY MASS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84940758260     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-014-0186-7     Document Type: Article

References (30)

1. Richter B, Banderia-Echtler E, Bergerhoff K, et al. Emerging role of dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4:753–68.
2. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.
3. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl-peptidase IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–94.
4. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–55.
5. He YL, Yamaguchi M, Tarao S, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. Int J Clin Pharm Ther. 2010;48:582–95.
6. Bergman AJ, Stevens C, Zhou YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55–72.
7. Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775–83.
8. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complicat. 2010;24:79–83.
9. Keating GM. Vildagliptin a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089–112.
10. Signorovitch JE, Wu EQ, Swallow E, et al. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus. A matching-adjusted indirect comparison of randomized trials. Clin Drug Invest. 2011;31:665–74.
11. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34:1247–58.
12. Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:112–20.
13. Saisho Y, Miyakoshi K, Tanaka M, et al. Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J. 2010;57:973–80.
14. The Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan. Tokyo: Nankodo; 2004 (in Japanese).
15. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
16. Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.
17. Eposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13:594–603.
18. Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;89:216–23.
19. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with sulfonylurea. Diabetes Obes Metab. 2008;11:1047–56.
20. Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:20–2.
21. Bando Y, Kanehara H, Aoki K, et al. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Invest. 2012;3:170–4.
22. Prato SD, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of & #x03B2;-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–67.
23. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881–5.
24. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed & #x03B2;-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103–9.
25. Goto A, Takaichi M, Kishimoto M, et al. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J. 2010;57:237–44.
26. Asano T, Kawamura M, Watanabe T, et al. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. J Jpn Diabetes Soc. 2008;51:759–63 (in Japanese).
27. Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J. 2011;58:315–22.
28. Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide-1 and cardiovascular risk. Nutr Metab Cardiovasc Dis. 2008;18:639–45.
29. Giorgino F, Leonardini A, Natalicchio A, et al. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest. 2011;34:69–77.
30. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29:14–25.